Table 5 Factors associated with viral relapse after treatment completion
Viral relapse | SVR12 | p value | |
|---|---|---|---|
Sex (male/female) | 9/14 | 73/60 | 0.18 |
Age 70 years or more/<70 years | 5/18 | 7/126 | 0.018 |
ALT (U/L) | 62.6 ± 38.0 | 63.6 ± 46.9 | 0.92 |
Platelet count (×104/µL) | 13.5 ± 4.5 | 15.9 ± 4.6 | 0.023 |
AFP (ng/mL) | 16.6 ± 21.8 | 12.3 ± 35.4 | 0.58 |
HCV-RNA (log copies/mL) | 6.6 ± 0.57 | 6.4 ± 0.69 | 0.14 |
IL28B (TT/non-TT) | 4/6 | 57/14 | 0.012 |
HCV Core aa70 (wild/mutant) | 1/2 | 33/9 | 0.14 |
HCV Core aa91 (wild/mutant) | 3/1 | 24/17 | 0.64 |
Treatment naïve/re-treatment | 10/13 | 66/66 | 0.65 |
Non-responders/others | 6/17 | 16/106 | 0.10 |
Peg-IFN adherence (%) | 88.6 ± 19.5 | 91.8 ± 18.6 | 0.46 |
RBV adherence (%) | 90.6 ± 43.9 | 84.8 ± 20.7 | 0.33 |
Histological fibrosis (F0-2/F3-4) | 7/6 | 52/25 | 0.35 |